Trial Profile
Phase II open-label trial of topical SD 101 for the treatment of chronic wounds and lesions in children with various types of epidermolysis bullosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2016
Price :
$35
*
At a glance
- Drugs Allantoin (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- 11 Jan 2016 According to an Amicus Therapeutics media release, Allantoin has been granted FDA breakthrough therapy designation for the treatment of lesions in patients suffering with Epidermolysis-bullosa in 2013 based on results of this trial.
- 24 Dec 2013 New trial record
- 01 Jun 2013 The full data set is expected to be presented at an upcoming scientific conference, according to a Scioderm media release.